Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gyroscope Targeting ‘Huge’ Population With Dry AMD Gene Therapy

Executive Summary

Bringing gene therapy to the masses: company raises extra £50m in series B fundraising for novel dry macular degeneration treatment

You may also be interested in...



Syncona Biotechs Face Up To Trial Delays Over COVID-19

Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.

Gyroscope Merger Creates Gene Therapy Biotech For Eye Disorders

A new UK/US biotech tie-up makes a company with the technology to deliver its gene therapies.

GSK-Partnered Alector Hit By Renewed Dementia Skepticism

Investors were spooked by mixed results from Alector’s lead candidate but the company’s CEO hit out at ‘hype’ around the biomarker  neurofilament light chain.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel